Altimmune Inc.
09/25/2025 | Press release | Distributed by Public on 09/25/2025 14:07
Proxy Results (Form 8-K)
Item 5.07 Submission of Matters to a Vote of Security Holders.
On September 25, 2025, Altimmune, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting"). As of August 12, 2025, the record date for the 2025 Annual Meeting, there were 88,257,253 shares of the Company's common stock outstanding and entitled to vote at the 2025 Annual Meeting. A total of 51,688,116 shares of common stock were present or represented by proxy at the 2025 Annual Meeting, representing 58.6% of the issued and outstanding shares entitled to vote at the meeting, representing a quorum. The proposals voted upon and the final results of the vote were as follows:
Proposal No. 1: Election of Directors. The results were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Broker |
|
|
Director |
|
For |
|
Withhold |
|
Non-Votes |
|
Jerome Durso, Chairman |
|
20,607,586 |
1,229,401 |
29,851,129 |
||
|
Vipin K. Garg, Ph.D. |
|
17,425,330 |
4,411,657 |
29,851,129 |
||
|
John M. Gill |
|
18,050,621 |
3,786,366 |
29,851,129 |
||
|
Philip L. Hodges |
|
14,680,278 |
7,156,709 |
29,851,129 |
||
|
Diane Jorkasky, M.D. |
|
14,778,350 |
7,058,637 |
29,851,129 |
||
|
Teri Lawver |
|
16,535,619 |
5,301,368 |
29,851,129 |
||
|
Wayne Pisano |
|
18,052,060 |
3,784,927 |
29,851,129 |
||
|
Mitchel Sayare, Ph.D. |
|
17,619,208 |
4,217,779 |
29,851,129 |
||
|
Klaus O. Schafer, M.D., MPH |
14,643,908 |
7,193,079 |
29,851,129 |
|||
|
Catherine Sohn, Pharm D |
14,454,283 |
7,382,704 |
29,851,129 |
Proposal No. 2: Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025. The results were as follows:
|
|
|
|
|
|
|
For |
|
Against |
|
Abstain |
|
48,959,891 |
|
1,355,769 |
1,372,456 |
Proposal No. 3: Advisory vote on the Compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules (referred to as the "say-on-pay" proposal). The results were as follows:
|
|
|
|
|
|
|
|
|
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
|
14,885,881 |
|
6,683,682 |
|
267,424 |
29,851,129 |
Proposal No. 4: Vote to authorize the adjournment of the 2025 Annual Meeting to enable the Board of Directors to solicit additional proxies. The results were as follows:
|
|
|
|
|
|
|
For |
|
Against |
|
Abstain |
|
33,695,815 |
|
16,363,206 |
1,629,095 |
Altimmune Inc. published this content on September 25, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 25, 2025 at 20:07 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]